AdAlta
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAAdAlta Ltd (1AD) is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein.
Contact Details
Unit 15, 2 Park Dr, BUNDOORA VIC 3083
03 9479 5159
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1165th | AdAlta | -22% | -32% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | AdAlta | $1.7m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Robert Peach, Non-Executive Director | 03 Jul 2024 |
| NEW ROLE: David Fuller, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Liddy McCall, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Paul MacLeman, Executive Chairman | 03 Nov 2020 |
| NEW ROLE: James Williams, Alternate Director | 03 Nov 2020 |
| NEW ROLE: Timothy Oldham, Managing Director, Chief Executive Officer | 03 Nov 2020 |
| NEW ROLE: Colin Boyan, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Cameron Jones, Chief Financial Officer, Company Secretary | 03 Nov 2020 |
